Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNC-T (SV-101) in Advanced Solid Tumors
NCT05544240Phase 1Recruiting
- Sponsor
- Williams Cancer Foundation
- Start
- Feb 2023
- Primary completion
- Jul 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SV-101 in metastatic solid tumor, sponsored by Williams Cancer Foundation. Primary endpoint: Antitumor activity. Started Feb 2023; status: recruiting.
02
Drugs
SV-101
03
Conditions
metastatic solid tumor
Beyond the preview
Go deeper on NCT05544240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05544240.